Processing

Please wait...

Settings

Settings

1. WO2000043042 - PARENTERAL METOLAZONE FORMULATIONS

Publication Number WO/2000/043042
Publication Date 27.07.2000
International Application No. PCT/US2000/001682
International Filing Date 21.01.2000
Chapter 2 Demand Filed 28.08.2000
IPC
A61K 31/517 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 47/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen
10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols ; Poloxamers; PEG/POE alkyl ethers
CPC
A61K 31/517
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 47/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Applicants
  • MEDEVA PHARMACEUTICALS MANUFACTURING, INC. [US/US]; 755 Jefferson Road Rochester, NY 14623, US
Inventors
  • SANTELLI, Ronald; US
  • TU, Yu-Hsing; US
Agents
  • POPOVICH, Thomas ; Popovich & Wiles, P.A. 1902 IDS Center 80 South 8th Street Minneapolis, MN 12423, US
Priority Data
09/237,69026.01.1999US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PARENTERAL METOLAZONE FORMULATIONS
(FR) FORMULATIONS DE MÉTOLAZONE PARENTÉRALES
Abstract
(EN)
The invention provides a method of making a pharmaceutical composition comprising a solution, which method comprises: (a) providing a solvent comprising propylene glycol, polyethylene glycol, polypropylene glycol, or glycerin; and (b) adding metolazone. The final concentration of metolazone in the solution is 9 mg/ml or more, the metolazone is not precipitated, and the concentration of metolazone is above its apparent equilibrium solubility. The invention also provides a pharmaceutical composition comprising a solution comprising: (a) a solvent other than water; and (b) 9 mg/ml or more of metolazone. The metolazone is not precipitated in this solution and the concentration of metolazone is above its apparent equilibrium solubility.
(FR)
L'invention concerne un procédé de fabrication d'une composition pharmaceutique renfermant une solution, le procédé comportant les étapes consistant à: (a) prévoir un solvant renfermant du propylène glycol, du polyéthylène glycol, du polypropylène glycol ou de la glycérine; et (b) ajouter une métolazone. La concentration finale de métolazone dans la solution est égale ou supérieure à 9 mg/ml, la métolazone n'est pas précipitée, et la concentration de métolazone est supérieure à son coefficient de solubilité d'équilibre apparente. L'invention concerne également une composition pharmaceutique qui renferme une solution contenant : (a) un solvant autre que de l'eau; et (b) une quantité égale ou supérieure à 9 mg/ml de métolazone. La métolazone n'est pas précipitée dans la solution et la concentration de métolazone est supérieure à son coefficient de solubilité d'équilibre apparente.
Also published as
Latest bibliographic data on file with the International Bureau